The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E{micro}-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B cell receptor signaling.

  • Suljagic M
  • Longo P
  • Bennardo S
 et al. 
  • 4


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Inhibition of antigen-dependent B-cell receptor (BCR) signaling is considered a promising therapeutic approach in CLL, but experimental in vivo evidence to support this view is still lacking. We have now investigated whether inhibition of BCR signaling with the selective Syk inhibitor fostamatinib disodium (R788) will affect the growth of the leukemias that develop in the Emu-TCL1 transgenic mouse model of CLL. Similar to human CLL these leukemias express stereotyped BCRs that react with autoantigens exposed on the surface of senescent or apoptotic cells, suggesting that they are antigen-driven. We show that R788 effectively inhibits BCR signaling in vivo, resulting in reduced proliferation and survival of the malignant B-cells and significantly prolonged survival of the treated animals. The growth-inhibitory effect of R788 occurs despite the relatively modest cytotoxic effect in vitro and is independent of basal Syk activity, suggesting that R788 functions primarily by inhibiting antigen-dependent BCR signals. Importantly, the effect of R788 was found to be selective for the malignant clones, as no disturbance in the production of normal B-lymphocytes was observed. Collectively, these data provide further rationale for clinical trials with R788 in CLL and establish the BCR signaling pathway as an important therapeutic target in this disease.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Mirza Suljagic

  • Pablo G Longo

  • Sara Bennardo

  • Emerald Perlas

  • Giuseppe Leone

  • Luca Laurenti

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free